Journal article
Outcomes and excess costs among patients with cardiovascular disease
Z Ademi, D Liew, E Zomer, A Gorelik, B Hollingsworth, PG Steg, DL Bhatt, CM Reid
Heart Lung and Circulation | Published : 2013
Abstract
Objective: To report on two-year cardiovascular (CV) event rates and quantify the cost of cardiovascular disease using the Australian Reduction of Atherothrombosis for Continued Health (REACH) registry. Methods: Prospective registry of 2873 patients with multiple risk factors (MRF), coronary artery disease (CAD), cerebrovascular disease (CerVD) and peripheral artery disease (PAD), recruited through 273 Australian general practitioners. Government reimbursement data from 2011 was used to calculate direct health care costs (pharmaceuticals, outpatient and hospitalisation costs). The main outcome of interest was two-year rates and associated excess costs of cardiovascular death, myocardial infa..
View full abstractGrants
Awarded by Bristol-Myers Squibb
Funding Acknowledgements
The global REACH Registry is sponsored by Sanofi-Aventis, Bristol-Myers Squibb and the Waksman Foundation (Tokyo, Japan), and is endorsed by the World Heart Federation. The REACH Registry enforces a no-ghostwriting policy. The sponsors provide logistical support. All manuscripts in the REACH Registry are led by independent authors who are not governed by the funding sponsors and are reviewed by an academic publication committee before submission. The funding sponsors have the opportunity to review manuscript submissions but do not have authority to change any aspect of a manuscript. A complete list of the REACH Registry Investigators appears in JAMA. 2006; 295(2): 180-189.